Immunovia to host webcast with opportunity to learn more about positive clinical validation of its next-generation pancreatic cancer test

LUND, Sweden, December 16, 2024 /PRNewswire/ — immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, published positive results in the clinical validation of its next-generation test for pancreatic cancer on December 9, 2024. As a follow-up, immunovia will host a webcast on Tuesday December 17 in 3:00 p.m. (Central European Time).

Jeff Borcherdingexecutive director, Norma Alonzo PalmaPhD, VP Clinical and Doctor (TASE:) Affairs and Lisa Ford (NYSE:)PhD, laboratory director will present additional details on the results and implications of the study. Dr. Aimee LucasHead of Gastroenterology and Hepatology of Mount Sinai and professor of Medicine Icahn School of Medicinewill join the webcast to share his perspective on the outcome of the study. The webcast will be held in English and will offer attendees the opportunity to ask questions. You are welcome to join, see details below.

Link to webcast: https://link.edgepilot.com/s/e8dd2ee9/T5WEGMPm6EqzxajKwPwQbw?u=https://creo-live.creomediamanager.com/dd81645b-30e0-45e1-af83-75a059fcba71

A recording of the presentation will be available at Immunovia website.

For more information, contact:
Karin Almqvist Liwendahl
CFO
karin.almqvist.liwendahl@immunovia.com

immunovia in summary

Immunovia AB is a diagnostic company whose mission is to increase the survival rates of pancreatic cancer patients through early detection. immunovia focuses on the development and commercialization of simple blood tests to detect proteins and antibodies that indicate that a high-risk individual has developed pancreatic cancer.

immunovia collaborates and engages with healthcare providers, leading experts, and patient advocacy groups to make its test available to people at increased risk for pancreatic cancer.

USA is the world’s largest market for pancreatic cancer screening. The company estimates that in the USA1.8 million people are at high risk for pancreatic cancer and could benefit from annual surveillance testing.

Immunovia The shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, visit www.immunovia.com

This information was provided by Cision http://news.cision.com

https://news.cision.com/immunovia-ab/r/immunovia-to-host-a-webcast-with-the-opportunity-to-learn-more-about-the-positive-clinical-validatio,c4082507

The following files are available for download: